GlassScriptPhysician profile
Blake A Embrey
NPI 1770007452
$5,025.16
in general payments reported to CMS, 2019-2025
34 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,771 · 2022: $1,766 · 2023: $193 · 2024: $176 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.72 | 2021-2024 | |
| Glaxosmithkline, LLC. | $605.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2021-2025 | Breztri |
| Novo Nordisk INC | $481.23 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.64 | 2021-2022 | |
| Corcept Therapeutics | $243.68 | 2023-2024 | Korlym |
| Dexcom, INC. | $216.17 | 2021-2022 | |
| Lilly USA, LLC | $198.88 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $144.47 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $128.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $127.00 | 2021-2022 | |
| Genentech USA, INC. | $125.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $110.44 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.34 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $86.05 | 2021-2022 | |
| Pfizer INC. | $73.38 | 2021 | |
| Pacira Therapeutics, INC. | $70.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.25 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $61.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.12 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $38.46 | 2021 | |
| Ironwood Pharmaceuticals, INC | $33.28 | 2021 | |
| Paratek Pharmaceuticals, INC. | $31.75 | 2025 | Nuzyra |
| Nevro Corp. | $31.34 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $25.21 | 2022 | |
| Vifor Pharma, INC. | $23.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.85 | 2021 | |
| Philips North America LLC | $22.84 | 2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $22.23 | 2022 | |
| Merck Sharp & Dohme LLC | $17.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.04 | 2021 | |
| Inogen, INC. | $9.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Embrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.